- Flora just announced the repurchase of $5 million of its outstanding common shares
- This repurchase aligns with its overall global expansion plan, and its move to grow its market reach
- These moves by Flora assure shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so
On June 16, 2022, Flora Growth (NASDAQ: FLGC) announced that its Board of Directors had authorized the repurchase of up to $5 million of its outstanding common shares. This came in the wake of the expiration of a one-year lockup period for specific shareholders who had acquired shares before the company’s Initial Public Offering (“IPO”).
While making the announcement, Luis Merchan, Flora’s Chairman and Chief Executive Officer (“CEO”), noted:
“Flora continues to move assertively to execute its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expenses.”
“We are confident in the company’s short, medium, and long-term growth prospects based on our strong in-market brand portfolio together with our cultivation and export capabilities in life sciences research,” he added (https://ibn.fm/maJ87).
This move to repurchase shares aligns with Flora’s overall global expansion plan that has seen the company follow through with acquisitions of strategic brands and entities in the industry. For example, earlier in the year, Flora acquired 100% equity interests in Just Brands LLC and High Roller Private Label LLC, the owners of the JustCBD brand, for a consideration of $16 million in cash and 9.5 million in privately issued Flora common shares (https://ibn.fm/pzSTz).
The repurchase also aligns with the company’s move to grow its market reach, having announced the expansion of its operational footprint in Europe and the United Kingdom. This expansion would bank on JustCBD’s 79 products registered with the UK Novel Foods, allowing for the distribution of its growing house of brands.
At the beginning of the year, Flora’s management reiterated how the cannabis sector was ripe for the picking. Most notably, they noted how great brands and cost advantages are optimal traits for the company’s long-term market leadership and return on investment (“ROI”), emphasizing the opportunities ahead. This outlook is shaping the company’s decision-making process halfway into 2022, even as it seeks to aggressively grow its market reach, product line, and customer numbers.
The global cannabidiol (“CBD”) industry is projected to post a CAGR of 21.3% over the forecast period (2021-2028), achieving a value of $47.22 billion, up from $4.9 billion. Flora looks to capitalize on this growth by making strategic acquisitions of key brands in the industry, aggressively expanding its market reach, and taking ownership of its brand, as evidenced by its recent repurchase of outstanding common shares.
“The repurchase program affords us the opportunity to increase our ownership in our portfolio of high quality brands through our shares, which in our view, are trading well below NAV,” noted Mr. Merchan.
These recent developments highlight Flora’s management’s confidence in where the company is headed and its potential for growth as the year progresses. It also assures shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so. As such, this only emphasizes Flora’s value as a good investment.
For more information, visit the company’s website at www.FloraGrowth.com.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC
